Skip to content
Research/Gene Therapy/AAV9-Follistatin

AAV9-Follistatin

AAV9-Follistatin is a gene therapy approach that uses an adeno-associated virus (AAV9) vector to deliver the follistatin gene. Follistatin is a protein that inhibits myostatin, a negative regulator of muscle growth, potentially enhancing muscle mass and strength. This therapy is significant for longevity and health optimization as it may help counteract age-related muscle loss and improve overall physical function.

Intelligence Profile

Research Papers

Currently, there appear to be no published research papers on "AAV9-Follistatin" in the PubMed database. However, there is an ongoing clinical trial related to this therapy.

The clinical trial, identified as NCT07443826, is titled "CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy." This trial is in the recruitment phase and spans Phase 1 and Phase 2. It aims to explore the effects of combining AAV9-Follistatin with a VEGF plasmid gene therapy to address muscle loss associated with aging. Currently, specific outcomes or data from this study are not available, as it is still in progress.

Given the lack of published literature, any conclusions about the efficacy or safety of AAV9-Follistatin are pending the results of ongoing studies.

Disclaimer: This content is for informational purposes only and should not be used as medical advice. Always consult healthcare professionals for medical concerns.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.